Your browser is no longer supported. Please, upgrade your browser.
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E8.38 EPS (ttm)10.72 Insider Own0.20% Shs Outstand223.53M Perf Week6.86%
Market Cap20.07B Forward P/E7.38 EPS next Y12.16 Insider Trans111.84% Shs Float221.52M Perf Month-4.68%
Income2.40B PEG0.64 EPS next Q2.70 Inst Own94.30% Short Float2.15% Perf Quarter-15.64%
Sales4.99B P/S4.02 EPS this Y4.80% Inst Trans0.14% Short Ratio1.86 Perf Half Y-9.48%
Book/sh50.91 P/B1.76 EPS next Y10.09% ROA15.80% Target Price141.05 Perf Year-35.85%
Cash/sh12.30 P/C7.30 EPS next 5Y13.10% ROE23.20% 52W Range72.67 - 141.86 Perf YTD-16.99%
Dividend- P/FCF10.40 EPS past 5Y26.80% ROI16.90% 52W High-36.72% Beta1.36
Dividend %- Quick Ratio3.70 Sales past 5Y17.40% Gross Margin92.10% 52W Low23.53% ATR5.03
Employees3082 Current Ratio4.30 Sales Q/Q22.60% Oper. Margin42.50% RSI (14)51.76 Volatility4.98% 6.60%
OptionableYes Debt/Eq0.23 EPS Q/Q675.80% Profit Margin48.20% Rel Volume0.65 Prev Close90.35
ShortableYes LT Debt/Eq0.22 EarningsApr 30 BMO Payout0.00% Avg Volume2.56M Price89.77
Recom2.00 SMA206.15% SMA50-4.89% SMA200-15.88% Volume1,669,250 Change-0.64%
Mar-17-20Downgrade Oppenheimer Outperform → Perform
Mar-05-20Downgrade BofA/Merrill Buy → Neutral $130 → $110
Jan-31-20Resumed RBC Capital Mkts Outperform $135
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight $170 → $128
Nov-12-19Initiated SunTrust Buy $125
Oct-17-19Resumed BofA/Merrill Buy $130
Sep-26-19Initiated William Blair Outperform
Jul-31-19Resumed JP Morgan Overweight $172
May-23-19Resumed Goldman Neutral $142
May-23-19Resumed Citigroup Buy
May-23-19Initiated Wedbush Outperform
Apr-10-19Resumed Raymond James Outperform $161
Mar-27-19Reiterated RBC Capital Mkts Outperform $165 → $186
Mar-21-19Reiterated Guggenheim Neutral $135
Feb-22-19Initiated Guggenheim Neutral $135
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
Dec-18-17Upgrade Robert W. Baird Neutral → Outperform $150
Apr-02-20 01:04PM  6 Health Care Companies Boosting Book Value
10:19AM  Vertex enters new era of leadership, drug development American City Business Journals
Apr-01-20 05:50PM  Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know Zacks
12:10PM  Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again Zacks
Mar-30-20 11:35AM  Cell and gene therapy firm raises $170M investment American City Business Journals
Mar-26-20 05:50PM  Alexion Pharmaceuticals (ALXN) Gains But Lags Market: What You Should Know Zacks
02:53PM  The Top 10 Biotechnology Companies Investopedia
Mar-22-20 05:04PM  Largest Insider Trades of the Week
Mar-19-20 06:29AM  Those Who Purchased Alexion Pharmaceuticals (NASDAQ:ALXN) Shares Five Years Ago Have A 53% Loss To Show For It Simply Wall St.
Mar-18-20 05:50PM  Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know Zacks
Mar-17-20 02:57PM  Top Health Care Stocks for April 2020 Investopedia +9.00%
Mar-11-20 07:46PM  Is Alexion Pharmaceuticals, Inc. (ALXN) A Good Stock To Buy? Insider Monkey -5.71%
Mar-09-20 01:30PM  6 Cheap Health Care Stocks -6.04%
Mar-05-20 06:25PM  Alexion Announces Upcoming Data Presentations at 72nd Annual Meeting of the American Academy of Neurology Business Wire
12:27PM  Biopharma Could Outperform Volatile Market, Analyst Says
Mar-02-20 09:36AM  Could a rare disease drug defeat the coronavirus? American City Business Journals
Feb-29-20 11:31AM  Alexion (ALXN) Down 6.3% Since Last Earnings Report: Can It Rebound? Zacks
Feb-27-20 08:30AM  Alexion Announces Launch of Alexion Charitable Foundation and Calls for Grantees Business Wire
Feb-26-20 06:30AM  Alexion to Present at the 40th Annual Cowen Health Care Conference Business Wire
Feb-24-20 05:44AM  How biotech Alnylam plans to make a profit, and what stands in its way American City Business Journals
Feb-20-20 04:01PM  Alexion to Present at the 9th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-11-20 05:27PM  Can Biotech ETFs Gain on Mixed Q4 Earnings Results? Zacks
Feb-10-20 06:28PM  Edited Transcript of ALXN earnings conference call or presentation 30-Jan-20 12:30pm GMT Thomson Reuters StreetEvents
Feb-05-20 04:03PM  In the highest ranks of Mass. corporate leadership, women still scarce American City Business Journals
Feb-04-20 07:40AM  Top Ranked Growth Stocks to Buy for February 4th Zacks
05:00AM  Alexion- Short Term Disappointment but Long Term Opportunity MoneyShow
Feb-03-20 05:30AM  Is Alexion Pharmaceuticals (NASDAQ:ALXN) Using Too Much Debt? Simply Wall St.
04:52AM  Results: Alexion Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates Simply Wall St.
Jan-31-20 03:02PM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales Zacks
10:43AM  Top Ranked Growth Stocks to Buy for January 31st Zacks
05:00AM  Families of rare-disease patients take on drug development, but face uphill battle American City Business Journals
Jan-30-20 04:26PM  Alexion Stumbles On Mixed Outlook Despite Strong Fourth-Quarter Earnings Investor's Business Daily -6.21%
10:15AM  Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
09:49AM  Recap: Alexion Pharmaceuticals Q4 Earnings Benzinga
07:55AM  Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Top Estimates Zacks
06:30AM  Alexion Reports Fourth Quarter and Full Year 2019 Results Business Wire
01:32AM  Alexion Earnings, Revenue Beat in Q4
Jan-29-20 02:04PM  $930 million sale of Blue Bell biopharma firm finalized American City Business Journals
08:56AM  Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More Zacks
08:45AM  Why Earnings Season Could Be Great for Alexion (ALXN) Zacks
08:45AM  Top Ranked Growth Stocks to Buy for January 29th Zacks
Jan-28-20 04:22PM  Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study Zacks
02:36PM  5 'Strong Buy' Biotech Stocks to Buy for 2020 Kiplinger
10:35AM  Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings? Zacks
09:29AM  Alexion Completes Acquisition of Achillion Business Wire
Jan-27-20 10:39AM  The Zacks Analyst Blog Highlights: Lear, SEI Investments, Alexion Pharmaceuticals and Apartment Investment and Management Zacks
10:25AM  Will Soliris, Ultomiris Drive Alexion's (ALXN) Q4 Earnings? Zacks
09:26AM  Amgen (AMGN) to Report Q4 Earnings: What's in the Cards? Zacks
08:32AM  Will Lower Revenues Dampen Corning's (GLW) Q4 Earnings? Zacks
08:10AM  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4? Zacks
Jan-24-20 02:54PM  Tesla's (TSLA) Unintended Acceleration Problem Zacks
09:57AM  Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma Zacks
09:55AM  What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings? Zacks
08:17AM  4 Top-Ranked Stocks Poised to Beat on Q4 Earnings Next Week Zacks
06:30AM  UPDATED TIME: Alexion Fourth Quarter and Full Year 2019 Results Conference Call at 7:30am ET on Thursday, January 30, 2020 Business Wire
Jan-23-20 12:31PM  Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
08:34AM  New Strong Buy Stocks for January 23rd Zacks
08:23AM  What's in Store for Align Technology's (ALGN) Q4 Earnings? Zacks
Jan-22-20 12:45PM  3 Reasons Why Alexion (ALXN) Is a Great Growth Stock Zacks
11:40AM  ALXN vs. QGEN: Which Stock Should Value Investors Buy Now? Zacks
09:20AM  5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates Zacks
08:53AM  Top Ranked Growth Stocks to Buy for January 22nd Zacks
Jan-21-20 08:57AM  Mersana Therapeutics (MRSN) Looks Good: Stock Adds 5.8% in Session Zacks
Jan-20-20 09:17AM  Top Ranked Growth Stocks to Buy for January 20th Zacks
08:17AM  New Strong Buy Stocks for January 20th Zacks
Jan-17-20 06:30AM  Alexion to Report Fourth Quarter and Full Year 2019 Results on Thursday, January 30, 2020 Business Wire
Jan-15-20 04:34PM  Alexion to Start Pivotal Study on Ultomiris for ALS in Q1 Zacks
10:02AM  3 Healthcare Stocks That Are Coming Back to Life TipRanks
08:22AM  Momenta (MNTA) Provides Pipeline Updates, Stock Rallies Zacks
05:39AM  Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure American City Business Journals
Jan-14-20 05:45PM  Alexion Pharmaceuticals (ALXN) Dips More Than Broader Markets: What You Should Know Zacks
08:53AM  Ultragenyx Provides Preliminary Crysvita 2019 Revenues Zacks
08:30AM  Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS Business Wire
Jan-13-20 10:17AM  Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari Zacks
10:14AM  Ultragenyx's Gene Therapy Positive in Genetic Disorder Study Zacks
09:54AM  Top Ranked Growth Stocks to Buy for January 13th Zacks
08:00AM  New Strong Buy Stocks for January 13th Zacks
Jan-10-20 12:03PM  11 Samp;P 500 Stocks That Could Soar 20% or More in 2020 Kiplinger
08:52AM  A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations Benzinga
Jan-09-20 05:10PM  Gilead (GILD) Inks License Deal with Xencor for HIV Candidate Zacks
02:24PM  Spiros Segalas Sells Tencent, Trims PayPal Position
11:30AM  Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year? Zacks
09:00AM  The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals Zacks
Jan-08-20 11:26AM  Incyte's Application for Pemigatinib Gets EMA's Validation Zacks
08:53AM  Amarin Posts '19 Preliminary Results, Gives 2020 Expense View Zacks
08:30AM  5 Top Value Picks to Counter Recent Stock Market Softness Zacks
08:13AM  3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020 Zacks
07:48AM  Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study Zacks
Jan-07-20 04:15PM  This Biotech Just Topped Alexion's Biggest Moneymaker And Rocketed Investor's Business Daily
12:02PM  Can a Drug's $500,000 Price Withstand Competition? Bloomberg
10:29AM  Apellis Stock Soars After Head-to-Head Drug Trial Vs Alexion
10:26AM  Waltham biotech's drug bests Alexion's blockbuster Soliris in new trial American City Business Journals
09:24AM  Apellis stock soars on positive data for potential Soliris competitor MarketWatch
08:40AM  These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen TipRanks
06:38AM  Apellis Pharmaceuticals Soars as Blood-Drug Test Outperforms Alexion's Therapy
Jan-06-20 05:50PM  Alexion Pharmaceuticals (ALXN) Gains But Lags Market: What You Should Know Zacks
12:10PM  Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again Zacks
09:55AM  Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store? Zacks
06:30AM  Alexion to Present at the 38th Annual J.P Morgan Healthcare Conference Business Wire
Jan-03-20 12:45PM  Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why Zacks
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER BROS. ADVISORS LPDirectorMar 18Buy82.0181,3796,673,9357,841,556Mar 18 06:46 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy79.7650,9024,059,7927,766,918Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy76.51102,4217,836,5857,720,234Mar 18 06:45 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy78.76265,29820,894,7537,626,298Mar 18 06:45 PM
Franchini Indrani LallEVP, Chief Compliance OfficerJul 01Sale132.784,500597,51029,627Jul 02 04:41 PM
SARIN ARADHANAChief Strategy & Business OffJun 21Sale132.0057876,29630,201Jun 24 04:45 PM
BAKER BROS. ADVISORS LPDirectorMay 30Sale120.9757,4496,949,754952,874May 30 05:16 PM
BAKER BROS. ADVISORS LPDirectorMay 29Sale122.20119,06214,548,851959,035May 30 05:16 PM
BAKER BROS. ADVISORS LPDirectorMay 28Sale126.53123,48915,624,859971,803May 30 05:16 PM